Oxford Biomedica PLC
FINPROM Findings
1“FY2026 revenues expected to reach between £220-240 million...2027 and 2028 expected revenue growth of 25-30% year-on-year...Long-term potential to approach operating EBITDA margins of c.30% over a five-to-six year period”
Multiple specific forward-looking revenue and margin targets spanning several years are presented as headline bullet points. While qualified elsewhere, the prominence risks creating undue expectations.
RNS Announcements
1Proposed Placing of New Ordinary Shares
THIS ANNOUNCEMENT, INCLUDING THE APPENDICES, AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICE SECTION OF THIS ANNOUNCEMENT. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATIO…
Board of Directors
10| Name | Role | Appointed | Status |
|---|---|---|---|
| Colin Michael Bond | Director | 2025-01-01 | active |
| Dr Frank Mathias | Director | 2023-03-27 | active |
| Dr Frederic Roch Doliveux | Non-Executive Director | 2020-06-24 | active |
| Dr Heather Elizabeth Preston | Non-Executive Director | 2018-03-15 | active |
| Dr. Lucinda Claire Crabtree | Director | 2024-09-02 | active |
| Kay Elizabeth Davies | Director | 2021-03-01 | active |
| Laurence Colette-Elise Espinasse | Director | 2024-07-24 | active |
| Namrata Prafulchandra Patel | Director | 2022-04-13 | active |
| Natalie Louise Walter | Director | 2019-07-24 | active |
| Peter Georg Soelkner | Director | 2024-03-15 | active |